2023

  1. ICD-10-CM Codes
    2. ›
  2. C00-D49
    3. ›
  3. C81-C96
    4. ›
  4. C91-
    5. ›
  5. 2023 ICD-10-CM Diagnosis Code C91

2023 ICD-10-CM Diagnosis Code C91

Lymphoid leukemia

    2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
  • C91 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
  • The 2023 edition of ICD-10-CM C91 became effective on October 1, 2022.
  • This is the American ICD-10-CM version of C91 - other international versions of ICD-10 C91 may differ.
Type 1 Excludes
Type 1 Excludes Help
A type 1 excludes note is a pure excludes. It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as C91. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
  • personal history of leukemia (
    ICD-10-CM Diagnosis Code Z85.6

    Personal history of leukemia

      2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code POA Exempt
    Applicable To
    • Conditions classifiable to C91-C95
    Type 1 Excludes
    Z85.6
    )
The following code(s) above C91 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to C91:
  • C00-D49
    2023 ICD-10-CM Range C00-D49

    Neoplasms

    Note
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
    Neoplasms
  • C81-C96
    2023 ICD-10-CM Range C81-C96

    Malignant neoplasms of lymphoid, hematopoietic and related tissue

    Type 2 Excludes
    • Kaposi's sarcoma of lymph nodes (C46.3)
    • secondary and unspecified neoplasm of lymph nodes (C77.-)
    • secondary neoplasm of bone marrow (C79.52)
    • secondary neoplasm of spleen (C78.89)
    Malignant neoplasms of lymphoid, hematopoietic and related tissue
Clinical Information
  • A malignant lymphocytic neoplasm of b-cell or t-cell lineage involving primarily the bone marrow and the peripheral blood. This category includes precursor or acute lymphoblastic leukemias and chronic leukemias.
  • A progressive, proliferative disease of blood cells, originating from lymphoid cells.
  • A type of cancer in which the bone marrow makes too many lymphocytes (white blood cells).
  • Leukemia associated with hyperplasia and overactivity of the lymphoid tissue; there are increased numbers of circulating malignant lymphocytes and lymphoblasts.
  • Leukemia associated with hyperplasia of the lymphoid tissues and increased numbers of circulating malignant lymphocytes and lymphoblasts.
Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
Code annotations containing back-references to C91:
  • Type 1 Excludes: D72.825
    ICD-10-CM Diagnosis Code D72.825

    Bandemia

      2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code
    Applicable To
    • Bandemia without diagnosis of specific infection
    Type 1 Excludes
ICD-10-CM Codes Adjacent To C91
C90.11 …… in remission
C90.12 …… in relapse
C90.2 Extramedullary plasmacytoma
C90.20 …… not having achieved remission
C90.21 …… in remission
C90.22 …… in relapse
C90.3 Solitary plasmacytoma
C90.30 …… not having achieved remission
C90.31 …… in remission
C90.32 …… in relapse
C91 Lymphoid leukemia
C91.0 Acute lymphoblastic leukemia [ALL]
C91.00 Acute lymphoblastic leukemia not having achieved remission
C91.01 Acute lymphoblastic leukemia, in remission
C91.02 Acute lymphoblastic leukemia, in relapse
C91.1 Chronic lymphocytic leukemia of B-cell type
C91.10 …… not having achieved remission
C91.11 …… in remission
C91.12 …… in relapse
C91.3 Prolymphocytic leukemia of B-cell type
C91.30 …… not having achieved remission

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Advertise with Us | License ICD10 Data

Copyright © | ICD10data.com